Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling

被引:122
作者
Lewis, Huw D.
Leveridge, Matthew
Strack, Peter R.
Haldon, Christine D.
O'Neil, Jennifer
Kim, Hellen
Madin, Andrew
Hannam, Joanne C.
Look, A. Thomas
Kohl, Nancy
Draetta, Giulio
Harrison, Timothy
Kerby, Julie A.
Shearman, Mark S.
Beherl, Dirk
机构
[1] Merck Sharp & Dohme Res Lab, Dept Mol & Cellular Neurosci, Harlow CM20 2QR, Essex, England
[2] Merck Sharp & Dohme Res Lab, Dept Med Chem, Harlow CM20 2QR, Essex, England
[3] Merck Res Labs, Dept Canc Biol & Therapeut, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
来源
CHEMISTRY & BIOLOGY | 2007年 / 14卷 / 02期
关键词
D O I
10.1016/j.chembiol.2006.12.010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this report, inhibitors of the gamma-secretase enzyme have been exploited to characterize the anti proliferative relationship between target inhibition and cellular responses in Notch-dependent human T cell acute lymphoblastic leukemia (T-ALL) cell lines. Inhibition of y-secretase led to decreased Notch signaling, measured by endogenous NOTCH intracellular domain (NICD) formation, and was associated with decreased cell viability. Flow cytometry revealed that decreased cell viability resulted from a G(0)/G(1) cell cycle block, which correlated strongly to the induction of apoptosis. These effects associated with inhibitor treatment were rescued by exogenous expression of NICD and were not mirrored when a markedly less active enantiomer was used, demonstrating the y-secretase dependency and specificity of these responses. Together, these data strengthen the rationale for using y-secretase inhibitors therapeutically and suggest that programmed cell death may contribute to reduction of tumor burden in the clinic.
引用
收藏
页码:209 / 219
页数:11
相关论文
共 58 条
[1]   Notch signaling in cancer [J].
Allenspach, EJ ;
Maillard, I ;
Aster, JC ;
Pear, WS .
CANCER BIOLOGY & THERAPY, 2002, 1 (05) :466-476
[2]   Notch signaling: Cell fate control and signal integration in development [J].
Artavanis-Tsakonas, S ;
Rand, MD ;
Lake, RJ .
SCIENCE, 1999, 284 (5415) :770-776
[3]  
Baker NE, 2000, BIOESSAYS, V22, P264, DOI 10.1002/(SICI)1521-1878(200003)22:3<264::AID-BIES8>3.0.CO
[4]  
2-M
[5]   Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression [J].
Balint, K ;
Xiao, M ;
Pinnix, CC ;
Soma, A ;
Veres, I ;
Juhasz, I ;
Brown, EJ ;
Capobianco, AJ ;
Herlyn, M ;
Liu, ZJ .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) :3166-3176
[6]   Perturbation of lkaros isoform selection by MLV integration is a cooperative event in NotchIC-induced T cell leukemogenesis [J].
Beverly, LJ ;
Capobianco, AJ .
CANCER CELL, 2003, 3 (06) :551-564
[7]   Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells [J].
Bocchetta, M ;
Miele, L ;
Pass, HI ;
Carbone, M .
ONCOGENE, 2003, 22 (01) :81-89
[8]   Is there a role for Notch signalling in human breast cancer? [J].
Brennan, K ;
Brown, AMC .
BREAST CANCER RESEARCH, 2003, 5 (02) :69-75
[9]   Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2 [J].
Capobianco, AJ ;
Zagouras, P ;
Blaumueller, CM ;
ArtavanisTsakonas, S ;
Bishop, JM .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (11) :6265-6273
[10]   Notch in lung development and lung cancer [J].
Collins, BJ ;
Kleeberger, W ;
Ball, DW .
SEMINARS IN CANCER BIOLOGY, 2004, 14 (05) :357-364